Neuberger Berman Group LLC grew its holdings in GlaxoSmithKline plc (NYSE:GSK) by 1.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 991,683 shares of the pharmaceutical company’s stock after acquiring an additional 15,660 shares during the period. Neuberger Berman Group LLC’s holdings in GlaxoSmithKline were worth $40,262,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of GSK. Renaissance Technologies LLC grew its stake in shares of GlaxoSmithKline by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares in the last quarter. FMR LLC grew its stake in shares of GlaxoSmithKline by 5.9% during the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after purchasing an additional 1,389,238 shares in the last quarter. Federated Investors Inc. PA grew its stake in shares of GlaxoSmithKline by 22.7% during the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after purchasing an additional 833,501 shares in the last quarter. Hotchkis & Wiley Capital Management LLC grew its stake in shares of GlaxoSmithKline by 7.3% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock worth $341,727,000 after purchasing an additional 569,600 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of GlaxoSmithKline by 504.4% during the third quarter. Point72 Asset Management L.P. now owns 604,419 shares of the pharmaceutical company’s stock worth $24,539,000 after purchasing an additional 504,419 shares in the last quarter. Institutional investors and hedge funds own 9.81% of the company’s stock.

GlaxoSmithKline plc (GSK) opened at $35.36 on Wednesday. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. GlaxoSmithKline plc has a 12 month low of $34.52 and a 12 month high of $44.53. The stock has a market cap of $86,814.95, a price-to-earnings ratio of 12.52, a price-to-earnings-growth ratio of 1.96 and a beta of 0.98.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be paid a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.70%. The ex-dividend date is Thursday, November 9th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is currently 163.12%.

In related news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.00% of the company’s stock.

A number of equities analysts recently commented on GSK shares. TheStreet upgraded shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. UBS upgraded shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $35.04 to $35.85 in a research note on Monday, November 27th. Zacks Investment Research upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Wednesday, October 18th. Argus reiterated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline in a research note on Thursday, August 31st. Finally, Investec downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $39.37.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/neuberger-berman-group-llc-boosts-holdings-in-glaxosmithkline-plc-gsk/1774454.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.